封面
市場調查報告書
商品編碼
2143028

原料藥及中間體市場:全球市場預測,2026-2032年

Pharmaceutical API & Intermediates Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,醫藥原料藥和中間體的市場規模將成長至 4,812.7 億美元,複合年成長率為 7.79%。

主要市場統計數據
基準年 2025 2845.4億美元
預計年份:2026年 3051.2億美元
預測年份 2032 4812.7億美元
複合年成長率 (%) 7.79%

藥物原料藥和中間體:概述

藥物活性成分(API)和中間體,涵蓋小分子化合物、生物製藥相關物質、高活性化合物以及特殊合成原料,構成了成品藥生產的核心。該領域受到嚴格的品質要求、監管、複雜的化學反應、對供應鏈的依賴以及從研發到商業化生產過程中可靠連續性的需求等因素的影響。

監管應對力與供應鏈轉型

產業趨勢正朝著採購多元化、供應商認證更加嚴格以及原料、中間體、原料藥生產和最終產品製造全過程透明度提高的方向發展。監管機構和製藥公司越來越重視可追溯性、資料完整性、環境管理、員工安全、緊急時應對計畫以及流程效能的穩定性。連續生產、先進的製程控制、環保化學以及產能提升等技術也在影響製造商如何在確保合規性的同時提高效率。

透過人工智慧改進開發和營運

人工智慧 (AI) 已被應用於製程路徑設計、反應預測、雜質評估、分析方法開發、製程最佳化、維護計劃和供應風險監控。其價值取決於高品質的實驗和生產數據、檢驗的模型、可解釋的輸出結果、網路安全以及人工監督。在法規環境中,人工智慧與實驗室系統、生產執行平台、品質流程和已記錄的檢驗框架相結合時最為有效,而不是被視為科學判斷的獨立替代方案。

全球原料藥和中間體生產的區域趨勢

在北美,先進的藥物研發、嚴格的品質體係以及對國家和地區韌性的重視相輔相成。拉丁美洲擁有成熟的藥品消費和生產能力,但對進口的依賴和監管差異仍是需要重點考慮的問題。在歐洲,在一個高度監管的生態系統中,品質、環境績效、技術轉移和供應穩定性至關重要。在中東,藥品生產能力和物流基礎設施正在發展,在地化政策正在影響投資重點。在非洲,儘管基礎設施、資金籌措和技能方面存在限制因素,但與基本藥物的取得和生產開發相關的機會仍然存在。亞太地區仍然是藥物化學、合約開發和生產(CDMO)、原料加工以及擴大國內藥品生產的重要中心,製造商仍在努力提高合規性和供應鏈透明度。

戰略集團分析:東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

東南亞國協正透過區域間貿易合作、製造業投資和不斷成長的醫療保健需求來增強其醫藥能力,但監管協調程度仍不均衡。金磚國家擁有龐大的人口需求、工業產能和在地化目標,但在監管成熟度和供應鏈結構方面存在顯著差異。歐盟優先考慮監管協調、環境管理和戰略自主。七國集團強調先進研究、高品質製造、韌性和關鍵藥物監測。海灣合作理事會國家正致力於推動醫療保健多元化、在地化生產和協調採購,並輔以對物流和工業基礎設施的投資。北約成員國日益重視藥品供應的連續性、戰略依賴性和安全的供應鏈網路,將其作為從韌性角度出發的更廣泛的準備要素。

各國對原料藥(API)和中間體的看法

澳洲依賴國際醫藥供應鏈網路,同時擁有強大的監管機構和研發能力。巴西擁有龐大的醫療保健基礎,對本地生產的興趣日益濃厚,同時也應對複雜的監管環境和工業環境。加拿大提供研發、生物製造和受監管的生產能力。中國支持大規模化工和製藥生產,同時持續專注於品質系統、環境合規和國際市場准入。法國、德國、義大利、西班牙和英國優先考慮韌性和永續生產,受益於完善的醫藥生態系統和先進的監管及研發能力。印度是醫藥製造和化學中間體的重要中心,並持續投資於合規、產能和製程升級。日本強調高品質生產、技術精準和嚴格的監管。墨西哥受益於其接近性北美供應鏈的地理優勢和成熟的製造業基礎。儘管面臨貿易、技術取得和供應鏈的限制,俄羅斯仍保持在醫藥和化學領域的實力。韓國將先進的生物製藥研發和製造技術與強大的技術基礎設施相結合。美國在醫藥創新、標準化生產和注重國內供應穩定的政策方面仍然是領先的中心。

領導層優先考慮建立更具韌性的API供應鏈

產業領導者需要識別直接供應商以外的依賴關係,這些依賴關係涵蓋原料、關鍵試劑、專用設備、物流路線以及單一生產場所的流程。在技​​術和經濟條件允許的情況下,他們應認證多家供應商,進行基於風險的供應商審核,並建立清晰的變更管理和技術轉移協議。投資重點應包括持續的製程監控、分析能力、檢驗的資料基礎設施、能源和溶劑效率、人才培養以及網路安全。此外,領導者還需要製定人工智慧應用管治,檢驗供應鏈中斷情景,根據產品關鍵性調整庫存水平,並與監管機構和策略合作夥伴協作制定透明的緊急應變計畫。

評估藥物原料藥(API)和中間體現狀的調查方法。

本執行摘要採用結構化的質性評估方法,對醫藥原料藥及中間體生態系進行分析。分析內容涵蓋生產能力、監管環境、醫藥需求推動要素、供應鏈依賴性、技術應用、永續性壓力、區域產業政策。分析整合了區域、集團和國家層面的觀點,並基於既定的行業特徵和政策主題,著重於檢驗的結構性因素,而非市場估算和預測、企業特定聲明或市場佔有率比較。

結論:品質、連續性和創新性並重。

醫藥原料藥及中間體產業正從以成本和產能為導向的模式,轉向同樣重視品質、連續性、透明度、永續性和技術適應性的模式。成功的關鍵在於建立一個具有韌性的多層次供應鏈網路,嚴格執行監管,採用高效且環保的生產流程,並負責任地運用人工智慧。那些能夠將卓越營運、策略採購和基於證據的風險管理相結合的企業,將更有能力支持跨區域的可靠藥品生產。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:原料藥及中間體市場:依產品類型分類

  • 活性藥物成分(API)
  • 醫藥中間體

第8章:藥物原料藥及中間體市場:依分子平台分類

  • 低分子化合物
  • 蛋白質和抗體
  • 複雜混合物和天然萃取物
  • 胜肽

第9章:原料藥及中間體市場:依生產管道分類

  • 化學合成
  • 細胞培養與發酵
  • 混合和半合成工藝
  • 天然資源的提取與回收

第10章:原料藥及中間體市場:依供應模式分類

  • 內部生產
  • 契約製造
  • 商戶供應

第11章:原料藥及中間體市場:依研發階段分類

  • 商業生產
  • 臨床開發
  • 臨床前和工藝開發

第12章:原料藥及中間體市場:依治療領域分類

  • 心血管系統
  • 腫瘤學
  • 抗感染藥物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
  • 胃腸道/代謝
  • 神經病學
  • 呼吸系統
  • 皮膚科

第13章:醫藥原料藥及中間體市場:依最終用戶分類

  • 製藥和生物技術公司
  • 契約製造組織

第14章 醫藥原料藥及中間體市場:依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第15章:原料藥及中間體市場:依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第16章:醫藥原料藥及中間體市場:依國家分類

  • 美國
  • 中國
  • 德國
  • 法國
  • 英國
  • 日本
  • 印度
  • 義大利
  • 加拿大
  • 西班牙
  • 俄羅斯
  • 韓國
  • 巴西
  • 墨西哥
  • 澳洲

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第18章:公司簡介

第19章:關鍵專家

Product Code: MRR-9C4233EE7C3E

The Pharmaceutical API & Intermediates Market is projected to grow by USD 481.27 billion at a CAGR of 7.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 284.54 billion
Estimated Year [2026] USD 305.12 billion
Forecast Year [2032] USD 481.27 billion
CAGR (%) 7.79%

Pharmaceutical API and Intermediates: Executive Overview

Pharmaceutical active pharmaceutical ingredients (APIs) and intermediates are central to the production of finished medicines, spanning small molecules, biologics-related materials, high-potency compounds, and specialized synthesis inputs. The sector is shaped by stringent quality requirements, regulatory oversight, complex chemistry, supply-chain dependencies, and the need for reliable manufacturing continuity across development and commercial production.

Regulatory Resilience and Supply-Chain Transformation

The landscape is shifting toward more diversified sourcing, stronger supplier qualification, and greater visibility across raw materials, intermediates, API production, and final dosage manufacturing. Regulators and pharmaceutical companies increasingly emphasize traceability, data integrity, environmental controls, worker safety, contingency planning, and consistent process performance. Continuous manufacturing, advanced process control, greener chemistry, and intensified production are also influencing how manufacturers improve efficiency while maintaining compliance.

Artificial Intelligence Improves Development and Operations

Artificial intelligence is being applied to route design, reaction prediction, impurity assessment, analytical method development, process optimization, maintenance planning, and supply-risk monitoring. Its value depends on high-quality experimental and manufacturing data, validated models, explainable outputs, cybersecurity, and human oversight. In regulated environments, AI is most effective when integrated with laboratory systems, manufacturing execution platforms, quality processes, and documented validation frameworks rather than treated as a standalone replacement for scientific judgment.

Regional Dynamics Across Global API and Intermediate Manufacturing

North America combines advanced pharmaceutical research, stringent quality systems, and interest in domestic and regional resilience. Latin America is supported by established pharmaceutical consumption and manufacturing capabilities, while import dependence and regulatory variation remain important considerations. Europe emphasizes quality, environmental performance, technology transfer, and supply security across a highly regulated ecosystem. The Middle East is developing pharmaceutical production capacity and logistics infrastructure, with localization policies influencing investment priorities. Africa presents opportunities linked to essential-medicine access and manufacturing development, alongside infrastructure, financing, and skills constraints. Asia-Pacific remains a major center for pharmaceutical chemistry, contract development and manufacturing, raw-material processing, and expanding domestic drug production, while manufacturers continue to address compliance consistency and supply-chain transparency.

Strategic Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN economies are strengthening pharmaceutical capabilities through regional trade links, manufacturing investment, and expanding healthcare demand, although regulatory harmonization remains uneven. BRICS members combine substantial population needs, industrial capacity, and localization objectives, but differ considerably in regulatory maturity and supply-chain structure. The European Union prioritizes harmonized regulation, environmental stewardship, and strategic autonomy. G7 economies emphasize advanced research, high-quality manufacturing, resilience, and oversight of critical medicines. GCC countries are pursuing healthcare diversification, local production, and coordinated procurement, supported by investment in logistics and industrial infrastructure. NATO members, viewed through a resilience lens, increasingly consider pharmaceutical continuity, strategic dependencies, and secure supply networks as elements of broader preparedness.

Country Perspectives on API and Intermediate Capabilities

Australia combines strong regulatory institutions and research capabilities with reliance on international pharmaceutical supply networks. Brazil has a broad healthcare base and growing interest in local production, while navigating complex regulatory and industrial conditions. Canada contributes research, biomanufacturing, and regulated production capacity. China supports extensive chemical and pharmaceutical manufacturing, with continued attention to quality systems, environmental compliance, and international market access. France, Germany, Italy, Spain, and the United Kingdom benefit from sophisticated pharmaceutical ecosystems and advanced regulatory and research capabilities, while prioritizing resilience and sustainable production. India is a major center for pharmaceutical manufacturing and chemical intermediates, with ongoing investment in compliance, capacity, and process sophistication. Japan emphasizes high-quality production, technological precision, and stringent oversight. Mexico benefits from proximity to North American supply chains and an established manufacturing base. Russia maintains pharmaceutical and chemical capabilities while facing trade, technology-access, and supply-chain constraints. South Korea combines advanced biopharmaceutical development, manufacturing expertise, and strong technology infrastructure. The United States remains a leading center for pharmaceutical innovation, regulated manufacturing, and policy attention to domestic supply security.

Leadership Priorities for a More Resilient API Supply Chain

Industry leaders should map dependencies beyond direct suppliers, including starting materials, critical reagents, specialized equipment, logistics routes, and single-site processes. They should qualify multiple sources where technically and economically practical, use risk-based supplier audits, and establish clear change-control and technology-transfer protocols. Investment priorities should include continuous process monitoring, analytical capability, validated data infrastructure, energy and solvent efficiency, workforce development, and cybersecurity. Leaders should also define governance for AI use, test scenarios for disruption, align inventories with product criticality, and collaborate with regulators and strategic partners on transparent resilience plans.

Methodology for Assessing the Pharmaceutical API and Intermediates Landscape

This executive summary uses a structured qualitative assessment of the pharmaceutical API and intermediates ecosystem. The analysis considers manufacturing capabilities, regulatory conditions, pharmaceutical demand drivers, supply-chain dependencies, technology adoption, sustainability pressures, and regional industrial policy. Regional, group, and country perspectives are synthesized from established sector characteristics and policy themes, with emphasis on verifiable structural factors rather than market estimates, forecasts, company-specific claims, or market-share comparisons.

Conclusion: Building Quality, Continuity, and Innovation Together

The pharmaceutical API and intermediates sector is evolving from a cost- and capacity-focused model toward one that places equal weight on quality, continuity, transparency, sustainability, and technological adaptability. Success will depend on resilient multi-tier supply networks, disciplined regulatory execution, efficient and cleaner processes, and responsible use of artificial intelligence. Organizations that connect operational excellence with strategic sourcing and evidence-based risk management will be better positioned to support dependable medicine production across diverse geographies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical API & Intermediates Market, by Product Type

  • 7.1. Introduction
  • 7.2. Active Pharmaceutical Ingredients (APIs)
  • 7.3. Pharmaceutical Intermediates

8. Pharmaceutical API & Intermediates Market, by Molecular Platform

  • 8.1. Introduction
  • 8.2. Small Molecules
  • 8.3. Proteins & Antibodies
  • 8.4. Complex Mixtures & Natural Extracts
  • 8.5. Peptides

9. Pharmaceutical API & Intermediates Market, by Production Route

  • 9.1. Introduction
  • 9.2. Chemical Synthesis
  • 9.3. Cell Culture & Fermentation
  • 9.4. Hybrid & Semisynthetic Processing
  • 9.5. Natural-Source Extraction & Recovery

10. Pharmaceutical API & Intermediates Market, by Supply Model

  • 10.1. Introduction
  • 10.2. Captive Manufacturing
  • 10.3. Contract Manufacturing
  • 10.4. Merchant Supply

11. Pharmaceutical API & Intermediates Market, by Development Stage

  • 11.1. Introduction
  • 11.2. Commercial Manufacturing
  • 11.3. Clinical Development
  • 11.4. Preclinical & Process Development

12. Pharmaceutical API & Intermediates Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Cardiovascular
  • 12.3. Oncology
  • 12.4. Anti-Infectives
    • 12.4.1. Antibiotic
    • 12.4.2. Antiviral
    • 12.4.3. Antifungal
  • 12.5. Alimentary Tract & Metabolism
  • 12.6. Neurology
  • 12.7. Respiratory System
  • 12.8. Dermatology

13. Pharmaceutical API & Intermediates Market, by End User

  • 13.1. Introduction
  • 13.2. Pharmaceutical & Biotechnology Companies
  • 13.3. Contract Manufacturing Organizations

14. Pharmaceutical API & Intermediates Market, by Region

  • 14.1. Introduction
  • 14.2. North America
  • 14.3. Europe
  • 14.4. Asia-Pacific
  • 14.5. Latin America
  • 14.6. Middle East
  • 14.7. Africa

15. Pharmaceutical API & Intermediates Market, by Group

  • 15.1. Introduction
  • 15.2. NATO
  • 15.3. G7
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. ASEAN
  • 15.7. GCC

16. Pharmaceutical API & Intermediates Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. China
  • 16.4. Germany
  • 16.5. France
  • 16.6. United Kingdom
  • 16.7. Japan
  • 16.8. India
  • 16.9. Italy
  • 16.10. Canada
  • 16.11. Spain
  • 16.12. Russia
  • 16.13. South Korea
  • 16.14. Brazil
  • 16.15. Mexico
  • 16.16. Australia

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Pharmaceutical API & Intermediates Market, Years Considered for the Study
  • FIGURE 2. Global Pharmaceutical API & Intermediates Market, Research Design
  • FIGURE 3. Global Pharmaceutical API & Intermediates Market, Research Framework
  • FIGURE 4. Global Pharmaceutical API & Intermediates Market, Data Triangulation
  • FIGURE 5. Global Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Pharmaceutical API & Intermediates Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Pharmaceutical API & Intermediates Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2025 vs 2032 (%)
  • FIGURE 9. Global Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Pharmaceutical API & Intermediates Market Size, by Production Route, 2025 vs 2032 (%)
  • FIGURE 11. Global Pharmaceutical API & Intermediates Market Size, by Production Route, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Pharmaceutical API & Intermediates Market Size, by Supply Model, 2025 vs 2032 (%)
  • FIGURE 13. Global Pharmaceutical API & Intermediates Market Size, by Supply Model, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Pharmaceutical API & Intermediates Market Size, by Development Stage, 2025 vs 2032 (%)
  • FIGURE 15. Global Pharmaceutical API & Intermediates Market Size, by Development Stage, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 17. Global Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Pharmaceutical API & Intermediates Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 19. Global Pharmaceutical API & Intermediates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Pharmaceutical API & Intermediates Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Pharmaceutical API & Intermediates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Pharmaceutical API & Intermediates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Pharmaceutical API & Intermediates Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Pharmaceutical API & Intermediates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Pharmaceutical API & Intermediates Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Pharmaceutical API & Intermediates Market Segmentation & Coverage
  • TABLE 2. Global Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Active Pharmaceutical Ingredients (APIs) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Active Pharmaceutical Ingredients (APIs) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Active Pharmaceutical Ingredients (APIs) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Pharmaceutical Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Pharmaceutical Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Pharmaceutical Intermediates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 11. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Proteins & Antibodies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Proteins & Antibodies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Proteins & Antibodies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Complex Mixtures & Natural Extracts Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Complex Mixtures & Natural Extracts Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Complex Mixtures & Natural Extracts Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Peptides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Peptides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Peptides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 24. Global Chemical Synthesis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Chemical Synthesis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Chemical Synthesis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Cell Culture & Fermentation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Cell Culture & Fermentation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Cell Culture & Fermentation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Hybrid & Semisynthetic Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Hybrid & Semisynthetic Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Hybrid & Semisynthetic Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Natural-Source Extraction & Recovery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Natural-Source Extraction & Recovery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Natural-Source Extraction & Recovery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 37. Global Captive Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Captive Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Captive Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Contract Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Contract Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Contract Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Merchant Supply Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Merchant Supply Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Merchant Supply Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 47. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Preclinical & Process Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Preclinical & Process Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Preclinical & Process Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 57. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Anti-Infectives Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Anti-Infectives Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Anti-Infectives Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Antibiotic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Antibiotic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Antibiotic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Antiviral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Antiviral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Antiviral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Antifungal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Antifungal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Antifungal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Alimentary Tract & Metabolism Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Alimentary Tract & Metabolism Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Alimentary Tract & Metabolism Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Respiratory System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Respiratory System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Respiratory System Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Dermatology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Dermatology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Dermatology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 88. Global Pharmaceutical & Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Pharmaceutical & Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Pharmaceutical & Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global Contract Manufacturing Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Contract Manufacturing Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Contract Manufacturing Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. North America Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. North America Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 97. North America Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 98. North America Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 99. North America Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 100. North America Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 101. North America Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 102. North America Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 103. North America Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 104. Europe Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Europe Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 106. Europe Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 107. Europe Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 108. Europe Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 109. Europe Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 110. Europe Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 111. Europe Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 112. Europe Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 115. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 116. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 117. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 118. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 119. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 120. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 121. Asia-Pacific Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. Latin America Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 123. Latin America Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 124. Latin America Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 125. Latin America Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 126. Latin America Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 127. Latin America Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 128. Latin America Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 129. Latin America Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 130. Latin America Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 131. Middle East Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 132. Middle East Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 133. Middle East Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 134. Middle East Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 135. Middle East Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 136. Middle East Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 137. Middle East Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 138. Middle East Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 139. Middle East Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. Africa Pharmaceutical API & Intermediates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 141. Africa Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 142. Africa Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 143. Africa Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 144. Africa Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 145. Africa Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 146. Africa Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 147. Africa Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 148. Africa Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. Global Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 150. NATO Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. NATO Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 152. NATO Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 153. NATO Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 154. NATO Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 155. NATO Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 156. NATO Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 157. NATO Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 158. NATO Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. G7 Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 160. G7 Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 161. G7 Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 162. G7 Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 163. G7 Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 164. G7 Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 165. G7 Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 166. G7 Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 167. G7 Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 168. European Union Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 169. European Union Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 170. European Union Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 171. European Union Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 172. European Union Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 173. European Union Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 174. European Union Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 175. European Union Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 176. European Union Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 177. BRICS Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 178. BRICS Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 179. BRICS Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 180. BRICS Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 181. BRICS Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 182. BRICS Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 183. BRICS Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 184. BRICS Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 185. BRICS Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 186. ASEAN Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 187. ASEAN Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 188. ASEAN Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 189. ASEAN Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 190. ASEAN Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 191. ASEAN Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 192. ASEAN Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 193. ASEAN Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 194. ASEAN Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 195. GCC Pharmaceutical API & Intermediates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 196. GCC Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 197. GCC Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 198. GCC Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 199. GCC Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 200. GCC Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 201. GCC Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 202. GCC Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 203. GCC Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 204. Global Pharmaceutical API & Intermediates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 205. United States Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 206. United States Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 207. United States Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 208. United States Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 209. United States Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 210. United States Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 211. United States Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 212. United States Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 213. United States Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 214. China Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 215. China Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 216. China Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 217. China Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 218. China Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 219. China Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 220. China Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 221. China Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 222. China Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 223. Germany Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 224. Germany Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 225. Germany Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 226. Germany Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 227. Germany Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 228. Germany Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 229. Germany Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 230. Germany Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 231. Germany Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. France Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 233. France Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 234. France Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 235. France Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 236. France Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 237. France Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 238. France Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 239. France Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 240. France Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. United Kingdom Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 242. United Kingdom Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 243. United Kingdom Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 244. United Kingdom Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 245. United Kingdom Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 246. United Kingdom Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 247. United Kingdom Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 248. United Kingdom Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 249. United Kingdom Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 250. Japan Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 251. Japan Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 252. Japan Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 253. Japan Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 254. Japan Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 255. Japan Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 256. Japan Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 257. Japan Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 258. Japan Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 259. India Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 260. India Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 261. India Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 262. India Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 263. India Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 264. India Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 265. India Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 266. India Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 267. India Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 268. Italy Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 269. Italy Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 270. Italy Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 271. Italy Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 272. Italy Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 273. Italy Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 274. Italy Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 275. Italy Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 276. Italy Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 277. Canada Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 278. Canada Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 279. Canada Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 280. Canada Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 281. Canada Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 282. Canada Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 283. Canada Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 284. Canada Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 285. Canada Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 286. Spain Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 287. Spain Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 288. Spain Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 289. Spain Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 290. Spain Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 291. Spain Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 292. Spain Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 293. Spain Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 294. Spain Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 295. Russia Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 296. Russia Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 297. Russia Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 298. Russia Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 299. Russia Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 300. Russia Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 301. Russia Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 302. Russia Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 303. Russia Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 304. South Korea Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 305. South Korea Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 306. South Korea Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 307. South Korea Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 308. South Korea Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 309. South Korea Pharmaceutical API & Intermediates Market Size, by Development Stage, 2017-2032 (USD Million)
  • TABLE 310. South Korea Pharmaceutical API & Intermediates Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 311. South Korea Pharmaceutical API & Intermediates Market Size, by Anti-Infectives, 2017-2032 (USD Million)
  • TABLE 312. South Korea Pharmaceutical API & Intermediates Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 313. Brazil Pharmaceutical API & Intermediates Market Size, 2017-2032 (USD Million)
  • TABLE 314. Brazil Pharmaceutical API & Intermediates Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 315. Brazil Pharmaceutical API & Intermediates Market Size, by Molecular Platform, 2017-2032 (USD Million)
  • TABLE 316. Brazil Pharmaceutical API & Intermediates Market Size, by Production Route, 2017-2032 (USD Million)
  • TABLE 317. Brazil Pharmaceutical API & Intermediates Market Size, by Supply Model, 2017-2032 (USD Million)
  • TABLE 318. Brazil Pharmaceutical API & Intermediates Mark